ID
41452
Description
Study ID: 107671 Clinical Study ID: 107671 Study Title: EGF107671 – A Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00437073 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: N/A Trade Name: capecitabine, topotecan, lapatinib Study Indication: Neoplasms, Breast; Recurrent Brain Metastases
Keywords
Versions (1)
- 10/13/20 10/13/20 -
Copyright Holder
GlaxoSmithKline
Uploaded on
October 13, 2020
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Lapatinib + Topotecan or + Capecitabine in Recurrent Brain Metastases from Breast Cancer; NCT00437073
Survival Follow-Up
- StudyEvent: ODM
Description
Survival Follow-Up
Alias
- UMLS CUI-1
- C1522577
- UMLS CUI-2
- C0038952
Description
Alive (finding)
Data type
text
Alias
- UMLS CUI [1]
- C2584946
Description
Alive (finding), Date last contact
Data type
date
Alias
- UMLS CUI [1,1]
- C2584946
- UMLS CUI [1,2]
- C0805839
Description
Cancer treatment, New
Data type
text
Alias
- UMLS CUI [1,1]
- C0920425
- UMLS CUI [1,2]
- C0205314
Description
Cancer treatment, New, Start Date
Data type
date
Alias
- UMLS CUI [1,1]
- C0920425
- UMLS CUI [1,2]
- C0205314
- UMLS CUI [1,3]
- C0808070
Similar models
Survival Follow-Up
- StudyEvent: ODM
C2985720 (UMLS CUI-2)
C2985720 (UMLS CUI [2])
C0038952 (UMLS CUI-2)
C0805839 (UMLS CUI [1,2])
C0205314 (UMLS CUI [1,2])
C0205314 (UMLS CUI [1,2])
C0808070 (UMLS CUI [1,3])